AstraZeneca To Resume Coronavirus Vaccine Trial In U.S.

Drugmaker AstraZeneca said Monday that late-stage trials showed its COVID-19 vaccine is highly effective, buoying the prospects of a relatively cheap, easy-to-store product that may become the vaccine of choice for the developing world.

The results are based on an interim analysis of trials in Britain and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine.

AstraZeneca is the third major drug company to report late-stage data for a potential COVID-19 vaccine as the world waits for scientific breakthroughs that will end a pandemic that has pummeled the world economy and so far led to 1.4 million deaths. But unlike the others, the Oxford-AstraZeneca vaccine doesn’t have to be stored at freezer temperatures, making it potentially easier to distribute, especially in developing countries.

“I think these are really exciting results,” Dr. Andrew Pollard, chief investigator for the trial, said at a news conference. “Because the vaccine can be stored at fridge temperatures, it can be distributed around the world using the normal immunization distribution system. And so our goal … to make sure that we have a vaccine that was accessible everywhere, I think we’ve actually managed to do that.”


Source :

AstraZeneca-Oxford COVID-19 vaccine looks effective and cheaper
AstraZeneca: COVID-19 vaccine shown to be 'highly effective'
AstraZeneca: COVID-19 vaccine shown to be ‘highly effective’, affordable, and easily transportable
AstraZeneca COVID-19 vaccine: Officials say it's less expensive, easier to store, and effective
COVID-19 vaccine developed by Oxford and AstraZeneca up to 90% effective, trial data show
AstraZeneca Covid-19 vaccine is 70% effective on average, early data show
AstraZeneca resumes COVID-19 vaccine clinical trial on UW campus
Another: AstraZeneca COVID-19 vaccine ‘highly effective’
AstraZeneca: COVID-19 vaccine ‘highly effective’ prevention
Oxford-Astrazeneca trial data show vaccine is at least 70 percent effective and easy to store as well